Monoclonal Antibodies: Past, Present and Future

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are highly specific immunoglobulins produced via hybridomas or recombinant DNA technology.
• Their antigen-binding capability stems from variable domains and complementarity-determining regions.
• Understanding mAb pharmacokinetics and preclinical safety is crucial due to unique disposition factors.

Purpose of the Study:

• To review the development and therapeutic applications of monoclonal antibodies.
• To highlight the successful use of mAbs in treating inflammatory conditions and cancers.
• To discuss considerations for early human studies and future antibody development.

Main Methods:

• Review of hybridoma and recombinant DNA technologies for mAb production.
• Analysis of factors influencing mAb pharmacokinetics and disposition.
• Examination of preclinical safety evaluation differences compared to small molecules.
• Case study review of therapeutic indications in inflammatory diseases and oncology.

Main Results:

• mAbs have revolutionized the treatment of inflammatory conditions like arthritis and inflammatory bowel disease.
• mAbs have shown significant efficacy as immunotherapy for solid tumors and various cancers.
• Immunogenicity impacts mAb pharmacokinetics and safety, requiring careful study design.

Conclusions:

• Monoclonal antibodies represent a significant advancement in modern medicine.
• Their targeted action offers revolutionary therapeutic benefits for autoimmune diseases and cancer.
• Future research directions include novel antibody development strategies.